Corbus Pharmaceuticals Holdings, Inc. filed a Form 8-K on November 16, 2026, disclosing additional Phase 1b clinical trial data for CRB-913 in obesity that were presented in a poster at ObesityWeek 2026 in Washington, D.C.
Key Highlights
- Primary efficacy result: The 60 mg dose of CRB-913 achieved a least-squares mean weight loss of 5.0% from baseline at week 12, with a p-value of less than 0.0001 versus placebo.
- All doses statistically significant: Weight loss was statistically significant at the 20 mg (2.8%), 40 mg (3.3%), and 60 mg (5.0%) cohorts compared to placebo (0.0%).
- Study size and design: CANYON-1 was a 16-week, double-blind, placebo-controlled, dose-ranging study enrolling 254 obese, non-diabetic adult participants at 15 investigational sites in the United States.
- Discontinuation rate: The treatment discontinuation rate due to adverse events across all study cohorts was 8.3%, which the filing states "is in line with published GLP-1 data."
- Psychiatric safety: No serious or severe treatment-emergent psychiatric adverse events were reported; only one of 188 CRB-913 participants reported transient, moderate depressive symptoms, and no cases of suicidal ideation were observed.
- Next steps: According to the filing, Corbus plans to engage with the FDA to discuss the data and development plans for CRB-913, and is also evaluating CRB-913 in potential combination with GLP-1 therapies.
CANYON-1 Phase 1b Data: Efficacy, Safety, and Study Design Details
According to the filing, the CANYON-1 Phase 1b trial enrolled 254 participants across four cohorts: placebo (n=66), CRB-913 20 mg (n=65), 40 mg (n=61), and 60 mg (n=62). All participants began at 20 mg daily and those assigned to higher-dose cohorts titrated up every two weeks. Participants were dosed for 12 weeks and followed for an additional 4 weeks. The filing states that CRB-913 "demonstrated rapid, statistically significant, and clinically meaningful weight loss at all dose levels, with no evidence of plateauing at any of the doses."
Beyond weight loss, the filing reported dose-dependent reductions in waist circumference and body mass index. At the 60 mg dose, waist circumference declined by 3.94 cm from baseline (p-value less than 0.0001 versus placebo's -0.84 cm). Among participants who completed the study at the 60 mg dose, the filing states that all lost weight, with 44.4% losing at least 5.0% from baseline, and the highest recorded weight loss in that cohort was 13.4% from baseline.
On the safety side, the filing reported that treatment-emergent gastrointestinal adverse events were all mild or moderate, with no serious or severe events. Nausea was reported in 15.4%, 26.2%, and 22.6% of participants in the 20 mg, 40 mg, and 60 mg cohorts, respectively, compared to 4.5% on placebo. Treatment discontinuations due to gastrointestinal adverse events occurred in only three participants across the entire study. The filing noted that "vomiting, nausea, and constipation occurred at lower rates and were less severe than those reported in published studies of oral GLP-1s." The filing also contains forward-looking statements, including those regarding FDA discussions and potential combination therapies, which the company described as subject to risks and uncertainties that could cause actual outcomes to differ materially.
What Was Disclosed
Corbus Pharmaceuticals disclosed Phase 1b clinical data for CRB-913 in obesity via an 8-K filed November 16, 2026, covering efficacy, safety, and psychiatric and gastrointestinal adverse event profiles from the 254-participant CANYON-1 trial, along with plans for FDA engagement.




Please wait processing your request...